BR112017004544A2 - single chain insulin, pharmaceutical composition and method for treating diabetes mellitus - Google Patents

single chain insulin, pharmaceutical composition and method for treating diabetes mellitus

Info

Publication number
BR112017004544A2
BR112017004544A2 BR112017004544-3A BR112017004544A BR112017004544A2 BR 112017004544 A2 BR112017004544 A2 BR 112017004544A2 BR 112017004544 A BR112017004544 A BR 112017004544A BR 112017004544 A2 BR112017004544 A2 BR 112017004544A2
Authority
BR
Brazil
Prior art keywords
insulin
chain insulin
chain
domain
amino acid
Prior art date
Application number
BR112017004544-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Weiss Michael
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of BR112017004544A2 publication Critical patent/BR112017004544A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112017004544-3A 2014-10-06 2015-10-06 single chain insulin, pharmaceutical composition and method for treating diabetes mellitus BR112017004544A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060167P 2014-10-06 2014-10-06
US62/060,167 2014-10-06
PCT/US2015/054263 WO2016057529A2 (en) 2014-10-06 2015-10-06 Biphasic single-chain insulin analogues

Publications (1)

Publication Number Publication Date
BR112017004544A2 true BR112017004544A2 (en) 2018-01-23

Family

ID=55653938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004544-3A BR112017004544A2 (en) 2014-10-06 2015-10-06 single chain insulin, pharmaceutical composition and method for treating diabetes mellitus

Country Status (10)

Country Link
US (2) US10392429B2 (cg-RX-API-DMAC10.html)
EP (1) EP3204410B1 (cg-RX-API-DMAC10.html)
JP (1) JP6829928B2 (cg-RX-API-DMAC10.html)
KR (1) KR102569743B1 (cg-RX-API-DMAC10.html)
CN (1) CN107108716B (cg-RX-API-DMAC10.html)
AU (1) AU2015328222B9 (cg-RX-API-DMAC10.html)
BR (1) BR112017004544A2 (cg-RX-API-DMAC10.html)
CA (1) CA2961037A1 (cg-RX-API-DMAC10.html)
IL (1) IL251503A0 (cg-RX-API-DMAC10.html)
WO (1) WO2016057529A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936563A1 (en) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
HK1255634A1 (zh) * 2015-12-23 2019-08-23 Case Western Reserve University 超稳胰岛素类似物在聚合物熔体中的包囊
AU2017361524B2 (en) * 2016-11-21 2022-06-02 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
HUE062719T2 (hu) * 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
BR112021005366A2 (pt) * 2018-09-21 2021-06-29 Case Western Reserve University análogo de insulina de cadeia simples, uso deste e método para reduzir o açúcar no sangue de um paciente
US12077568B2 (en) 2018-10-01 2024-09-03 University Of Houston System Engineered active single-polypeptide chain insulin analogs
US20220002373A1 (en) * 2018-11-19 2022-01-06 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
CA3139946A1 (en) * 2019-05-17 2020-11-26 Case Western Reserve University Variant single-chain insulin analogues
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20220280614A1 (en) * 2019-08-02 2022-09-08 Case Western Reserve University Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations
IL296090A (en) * 2020-03-02 2022-11-01 Thermalin Inc Compositions containing rapid-acting insulin analogues
EP4255469A4 (en) * 2020-12-07 2025-01-22 Case Western Reserve University ACYLATED SINGLE-CHAIN INSULIN ANALOGUES
CZ310198B6 (cs) * 2021-07-07 2024-11-13 Ústav organické chemie a biochemie AV ČR, v. v. i. Deriváty inzulínu se zvýšenou tepelnou stabilitou
WO2023041758A1 (en) 2021-09-20 2023-03-23 Kyon Biotech Ag Arginase-insulin fusion protein
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
WO1990001038A1 (en) 1988-07-20 1990-02-08 Nordisk Gentofte A/S Human insulin analogs and preparations containing them
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DE3936876A1 (de) 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK158390D0 (da) 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
TW224471B (cg-RX-API-DMAC10.html) 1991-11-26 1994-06-01 Lilly Co Eli
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
DE19652713C2 (de) 1996-12-18 2001-11-22 Aventis Pharma Gmbh Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
AU2002346490A1 (en) 2001-12-20 2003-07-09 Eli Lilly And Company Insulin molecule having protracted time action
WO2003080666A2 (en) 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research An adipocyte insulin and a method of treating diabetes
JP4602075B2 (ja) 2002-05-06 2010-12-22 トーマス・ジェファーソン・ユニバーシティ 脳の健康に効果のあるインスリン関連ペプチド
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
TWI345587B (en) 2003-06-17 2011-07-21 Sembiosys Genetics Inc Methods for the production of insulin in plants
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
ATE513921T1 (de) * 2005-08-16 2011-07-15 Novo Nordisk As Verfahren zur herstellung reifer insulinpolypeptide
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US8192857B2 (en) 2006-03-04 2012-06-05 Enerdel, Inc. Battery assembly and method of forming the same
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
AU2009240636A1 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
WO2009133099A2 (en) * 2008-04-28 2009-11-05 Novo Nordisk A/S Insulin precursors for diabetes treatment
EP2318432B1 (en) 2008-07-31 2015-09-02 Case Western Reserve University Halogen-stabilized insulin
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
RU2012123642A (ru) 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
BR112012020481A2 (pt) 2010-02-22 2017-01-10 Univ Case Western Reserve método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.
JP5969469B2 (ja) * 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
MX2015005662A (es) * 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.

Also Published As

Publication number Publication date
EP3204410A4 (en) 2018-03-07
KR20170064533A (ko) 2017-06-09
WO2016057529A2 (en) 2016-04-14
WO2016057529A3 (en) 2016-11-03
EP3204410A2 (en) 2017-08-16
US10392429B2 (en) 2019-08-27
CN107108716B (zh) 2026-06-19
KR102569743B1 (ko) 2023-08-23
AU2015328222B9 (en) 2020-12-24
US20190375814A1 (en) 2019-12-12
JP6829928B2 (ja) 2021-02-17
CA2961037A1 (en) 2016-04-14
JP2017536337A (ja) 2017-12-07
CN107108716A (zh) 2017-08-29
US11142560B2 (en) 2021-10-12
AU2015328222A1 (en) 2017-03-16
US20180265560A1 (en) 2018-09-20
IL251503A0 (en) 2017-05-29
EP3204410B1 (en) 2021-01-20
AU2015328222B2 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
WO2016057529A3 (en) Biphasic single-chain insulin analogues
AR110751A1 (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr)
BR112019011228A2 (pt) compostos como agonistas do receptor de glp1/glucagon/gip trigonais peptídicos
CL2018001695A1 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
AR098736A1 (es) Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa)
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
DOP2017000248A (es) PROTEÍNA DE UNIÓN A RGMa Y SU USO
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
MX380191B (es) Combinaciones de modalidades para el tratamiento de la diabetes.
AR105816A2 (es) Derivados de exendina-4 funcionalizada
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
AR099976A1 (es) Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4
BR112016028520A2 (pt) métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112017011398A2 (pt) métodos e composições que usam polipeptídeos variantes de klotho
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
MX2016006049A (es) Mimeticos de calcitonina para tratar enfermedades y trastornos.
WO2016023898A3 (en) Intracellular antigen binding
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
PL417544A1 (pl) Sposób modyfikacji sekwencji polipeptydów oraz jej zastosowanie
BR112015017909A2 (pt) redução do risco de doença autoimune
WO2015168488A3 (en) Islet amyloid polypeptides with improved solubility

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.